Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. reports developments tied to its medical-device business for superficial radiotherapy treatments for oncological and non-oncological skin conditions. The company’s updates center on SRT and IG-SRT technology, including systems used in the treatment of non-melanoma skin cancer and keloids, as well as products and services that support dermatology and radiation-oncology practices.
Recurring news topics include quarterly results, reimbursement and CPT coding for superficial radiotherapy, customer acquisition programs, financing options through Sensus Healthcare Financial Services, installed-base software such as Sensus Link, Fair Deal Agreement activity, international customer development, and commercial or legal matters related to product sales and deployments.
Sensus Healthcare (Nasdaq: SRTS) announced key executive promotions as part of its strategy for long-term growth. Michael J. Sardano has been promoted to President, while Christopher Machuzak and Jeffrey Starling are now Vice Presidents of Sales for the West and East Coasts, respectively. This decision reflects the company's commitment to develop talent internally and enhance its leadership team. The announcement also included the retirement of Executive Vice President and Co-founder Steve Cohen. These changes aim to leverage leadership strengths and drive sustained sales growth, especially post-COVID-19.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced a conference call on February 10, 2022, at 4:30 p.m. ET to discuss Q4 and full-year 2021 financial results. The call will include a business update and a review of recent and upcoming milestones. Interested parties can join the call via dial-in or a live webcast accessible through the company's website. Sensus Healthcare specializes in non-invasive and minimally invasive treatments through advanced technologies like the Sculptura™ system and SRT-100™ for oncological and non-oncological conditions.
Sensus Healthcare (SRTS) announces participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Joe Sardano will present a pre-recorded session available on-demand starting January 10 at 7:00 a.m. ET. Attendees can access the presentation via the company’s investor relations page. Additionally, Sensus management is open to virtual 1x1 meetings during the J.P. Morgan Healthcare Conference from January 10-14. Interested parties can schedule meetings through email.
Sensus Healthcare (Nasdaq: SRTS) anticipates achieving record sales exceeding $25 million for 2021, along with positive EBITDA and net income for both Q4 and the full year. The company's growth is attributed to strong performance during the pandemic recovery. Sensus has also begun exclusive U.S. distribution of its newly FDA-cleared TransDermal Infusion System™, which will be presented at the Winter Clinical Dermatology Conference on January 15, 2022. This system aims to enhance drug absorption in non-invasive aesthetics, indicating potential for broader market interest.
Sensus Healthcare (Nasdaq: SRTS) has signed an exclusive U.S. distribution agreement with Mattioli Eng. Italia S.P.A. for its FDA-cleared TransDermal Infusion System, a non-invasive drug delivery technology. Beginning immediately, Sensus will market this system to dermatologists for various applications, such as skin rejuvenation and pre- and post-plastic surgery treatments. The system allows for the painless delivery of drugs like Botox and hyaluronic acid, enhancing patient care and offering a competitive edge in the aesthetic dermatology field.
Sensus Healthcare (SRTS) reported a strong third quarter for 2021, achieving revenues of $5.5 million, a 244% increase from $1.6 million in Q3 2020. This marks the company’s first profitable quarter, with a net income of $0.2 million or $0.01 per diluted share, improving from a net loss of $(1.7) million a year prior. The company shipped 14 systems during the quarter and reaffirmed expectations for continued growth and profitability into Q4 and 2021. Cash reserves stood at $16.4 million with no long-term debt.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on November 4, 2021, at 4:30 p.m. Eastern time to discuss its third quarter 2021 financial results. Management will provide a business update and discuss recent and upcoming milestones. Investors can access the call by dialing 800-285-6670 (U.S.) or 832-553-9961 (International), and the call will also be available via live webcast. Following the call, a replay will be accessible via telephone and online. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a virtual fireside chat with CEO Joseph Sardano and CFO Javier Rampolla on October 19, 2021, at 11:00 a.m. ET. This session, organized by Maxim Group LLC and M-Vest, invites professional investors to register in advance. A 48-hour replay will be available post-event on the company’s investor website. Sensus Healthcare specializes in innovative, non-invasive treatments for oncological and non-oncological conditions, including its Sculptura™ system and SRT-100™ technology.
Sensus Healthcare (Nasdaq: SRTS) has received a five-year license renewal from the Chinese Health Authority to market its SRT-100™ system for treating non-melanoma skin cancer and keloids in Greater China. The new license, effective until December 2026, reflects the company's successful presence with 46 units installed in various medical facilities across China. The CEO expressed optimism about post-pandemic sales recovery and remarked on a new distribution agreement with Ekpac Healthcare. Sensus also anticipates marketing authorization for its Sculptura™ system by late 2022.
Sensus Healthcare (Nasdaq: SRTS) announces participation in the upcoming Fall Clinical Dermatology Conference from October 21-24, 2021, in Las Vegas. Over 1,200 physicians are registered to attend this first major in-person dermatology event in 18 months. Key opinion leaders will present on superficial radiation therapy (SRT) for non-melanoma skin cancer. CEO Joe Sardano emphasizes strong sales momentum for the second half of 2021, driven by favorable reimbursement changes and a backlog of orders. Sensus anticipates achieving profitability this year.